Cargando…

Combination therapy for high-volume versus low-volume metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis

Purpose: To conduct a systematic review and network meta-analysis (NMA) to compare the efficacy of currently available combination therapies in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Methods: Qualified publications were searched in the PubMed, Embase, and Cochrane CENTRA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jian, Tengteng, Zhan, Yang, Yu, Ying, Yu, Kai, Hu, Rui, Wang, Jixue, Lu, Ji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157498/ https://www.ncbi.nlm.nih.gov/pubmed/37153773 http://dx.doi.org/10.3389/fphar.2023.1148021

Ejemplares similares

Systemic triplet therapy for metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis
por: Jian, Tengteng, et al.
Publicado: (2022)

Achieving Consensus for Management of Hormone-Sensitive, Low-Volume Metastatic Prostate Cancer in Italy
por: Verzoni, Elena, et al.
Publicado: (2022)

Prognostic Factors for Hormone Sensitive Metastatic Prostate Cancer: Impact of Disease Volume
por: Alhanafy, Alshimaa Mahmoud, et al.
Publicado: (2018)

Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis
por: Yanagisawa, Takafumi, et al.
Publicado: (2022)

Intra-therapeutic dosimetry of [(177)Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome
por: Peters, Steffie M. B., et al.
Publicado: (2021)

Editorial: Autophagy in inflammation related diseases, volume II
por: Shao, Bo-Zong, et al.
Publicado: (2023)

Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy
por: Oing, C., et al.
Publicado: (2023)

Editorial: Targeted cancer therapies, from small molecules to antibodies, volume II
por: Su, Chao-Yue, et al.
Publicado: (2023)

Impact of National Volume-Based Procurement on the Procurement Volumes and Spending for Antiviral Medications of Hepatitis B Virus
por: Yuan, Jing, et al.
Publicado: (2022)

Editorial: Microbiome in IBD: From Composition to Therapy, Volume II
por: Liu, Ning-Ning, et al.
Publicado: (2023)

Editorial: Purinergic pharmacology, Volume II
por: Ciruela, Francisco, et al.
Publicado: (2023)

Editorial: Eicosanoids in cancer, Volume II
por: Patrignani, Paola, et al.
Publicado: (2023)

Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy
por: Lin, Yen-Chi, et al.
Publicado: (2021)

Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer
por: Ueda, Takashi, et al.
Publicado: (2021)

Impact of the Pilot Volume-Based Drug Purchasing Policy in China: Interrupted Time-Series Analysis with Controls
por: Chen, Yilin, et al.
Publicado: (2021)

Combination therapy in metastatic hormone-sensitive prostate cancer: is three a crowd?
por: Davis, Ian D.
Publicado: (2022)

Economic Evaluation of Combination Therapy Versus Monotherapy for Treatment of Benign Prostatic Hyperplasia in Hong Kong
por: Wu, David Bin-Chia, et al.
Publicado: (2018)

Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis
por: Hu, Xin, et al.
Publicado: (2019)

Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis
por: Guo, Zhuifeng, et al.
Publicado: (2022)

Editorial: New insights into renal fibrosis and therapeutic effects of natural products volume II
por: Chen, Dan-Qian, et al.
Publicado: (2022)

Editorial: Venoms, animal and microbial toxins, volume II
por: Cao, Zhijian, et al.
Publicado: (2022)

Editorial: Current Aspects in Chemopreventive Strategies, Volume II
por: Tuli, Hardeep Singh, et al.
Publicado: (2022)

Editorial: Antimalarial chemotherapy in the XXIst century, volume II
por: Gomes, Paula, et al.
Publicado: (2023)

Editorial: Cannabidiol treatment in neurotherapeutic interventions, volume II
por: Gonzalez-Cuevas, Gustavo, et al.
Publicado: (2023)

Advancements in the treatment of metastatic hormone-sensitive prostate cancer
por: Li, Hengping, et al.
Publicado: (2022)

Editorial Comment: Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer
por: Lott, Felipe
Publicado: (2020)

Treatment Intensification for Low-risk Metastatic Hormone-sensitive Prostate Cancer: The Time Is Now
por: McKay, Rana R.
Publicado: (2022)

Prostate radiotherapy for metastatic hormone sensitive prostate cancer—myth or reality?
por: Onal, Cem
Publicado: (2019)

Editorial: Imaging technology in oncology pharmacological research, volume II
por: Zeng, Qi, et al.
Publicado: (2022)

Editorial: Chronic Inflammation and Neurodegeneration in Retinal Disease, Volume II
por: Bucolo, Claudio, et al.
Publicado: (2022)

Editorial: Hydrogen sulfide: Physiology, Pharmacology and Toxicology, Volume II
por: Bian, Jin-Song
Publicado: (2022)

Editorial: Pharmacological approaches targeting neutrophilic inflammation: Volume II
por: Sokolov, Alexey V., et al.
Publicado: (2022)

Editorial: Resolution of inflammation: Mechanisms, mediators and biomarkers: Volume II
por: Patrignani, Paola, et al.
Publicado: (2022)

Editorial: Neurodegeneration, cell signaling and neuroreparative strategies, Volume II
por: Vaz, Ana Rita, et al.
Publicado: (2023)

Editorial: Experimental models of epilepsy and related comorbidities, Volume II
por: Shaikh, Mohd Farooq, et al.
Publicado: (2023)

Editorial: Medication safety in COVID-19 management, Volume II
por: Das, Saibal
Publicado: (2023)

Editorial: Receptor biology and cell signaling in diabetes: volume II
por: Srivastava, Swayam Prakash, et al.
Publicado: (2023)

Editorial: Neuroprotection and disease modification in Parkinson’s disease: Volume II
por: Otero-Losada, Matilde, et al.
Publicado: (2023)

Editorial: Application of plant secondary metabolites to pain neuromodulation, volume II
por: Singla, Rajeev K., et al.
Publicado: (2022)

Editorial: Novel therapeutic approaches for the treatment of ocular disease, Volume II
por: Thermos, Kyriaki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_teror508v1131lrurmgrl9fc85